What is a stock summary page? Click here for an overview.
Business Description
Coherus BioSciences Inc
NAICS : 541714
SIC : 2836
ISIN : US19249H1032
Compare
Compare
Traded in other countries / regions
CHRS.USA8C5.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-11-06Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.47 | |||||
| Equity-to-Asset | -0.29 | |||||
| Debt-to-Equity | -2.05 | |||||
| Debt-to-EBITDA | 4.43 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.58 | |||||
| Beneish M-Score | -4.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.7 | |||||
| 3-Year EPS without NRI Growth Rate | 32.4 | |||||
| 3-Year FCF Growth Rate | 29.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 19.31 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.33 | |||||
| 9-Day RSI | 38.38 | |||||
| 14-Day RSI | 38.69 | |||||
| 3-1 Month Momentum % | -39.46 | |||||
| 6-1 Month Momentum % | -3.37 | |||||
| 12-1 Month Momentum % | -57.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.21 | |||||
| Quick Ratio | 0.96 | |||||
| Cash Ratio | 0.45 | |||||
| Days Inventory | 189.08 | |||||
| Days Sales Outstanding | 273.12 | |||||
| Days Payable | 124.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.5 | |||||
| Shareholder Yield % | 158.14 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.97 | |||||
| Operating Margin % | -41.83 | |||||
| Net Margin % | 10.68 | |||||
| FCF Margin % | -7.66 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 4.72 | |||||
| ROIC % | -56.38 | |||||
| 3-Year ROIIC % | 783.08 | |||||
| ROC (Joel Greenblatt) % | 526.57 | |||||
| ROCE % | 25.08 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 4.21 | |||||
| Price-to-Owner-Earnings | 1.06 | |||||
| PS Ratio | 0.38 | |||||
| EV-to-EBIT | 4.29 | |||||
| EV-to-Forward-EBIT | 3.97 | |||||
| EV-to-EBITDA | 3.92 | |||||
| EV-to-Forward-EBITDA | 3.93 | |||||
| EV-to-Revenue | 0.89 | |||||
| EV-to-Forward-Revenue | 1.39 | |||||
| EV-to-FCF | -12.2 | |||||
| Price-to-GF-Value | 0.23 | |||||
| Earnings Yield (Greenblatt) % | 23.31 | |||||
| FCF Yield % | -22.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CHRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coherus BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 266.96 | ||
| EPS (TTM) ($) | 0.19 | ||
| Beta | 1.07 | ||
| 3-Year Sharpe Ratio | -0.61 | ||
| 3-Year Sortino Ratio | -0.83 | ||
| Volatility % | 86.19 | ||
| 14-Day RSI | 38.69 | ||
| 14-Day ATR ($) | 0.093079 | ||
| 20-Day SMA ($) | 0.922715 | ||
| 12-1 Month Momentum % | -57.77 | ||
| 52-Week Range ($) | 0.6603 - 2.61 | ||
| Shares Outstanding (Mil) | 115.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coherus BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coherus BioSciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Coherus BioSciences Inc Frequently Asked Questions
What is Coherus BioSciences Inc(CHRS)'s stock price today?
The current price of CHRS is $0.80. The 52 week high of CHRS is $2.61 and 52 week low is $0.66.
When is next earnings date of Coherus BioSciences Inc(CHRS)?
The next earnings date of Coherus BioSciences Inc(CHRS) is 2025-05-09 Est..
Does Coherus BioSciences Inc(CHRS) pay dividends? If so, how much?
Coherus BioSciences Inc(CHRS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers